

# Jasleen K Sodhi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/568325/jasleen-k-sodhi-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

295  
citations

10  
h-index

16  
g-index

34  
ext. papers

397  
ext. citations

4.8  
avg, IF

4.1  
L-index

#	Paper	IF	Citations
31	Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. <i>Pharmaceutical Research</i> , <b>2021</b> , 38, 1639-1644	4.5	0
30	Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 3546-3559	8.3	9
29	International Society for the Study of Xenobiotics (ISSX) New Investigator Group Committee 2019-2020 concluding remarks. <i>Drug Metabolism Reviews</i> , <b>2021</b> , 53, 279-284	7	1
28	Pharmacogenomics in the era of next generation sequencing - from byte to bedside. <i>Drug Metabolism Reviews</i> , <b>2021</b> , 53, 253-278	7	8
27	Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption. <i>Pharmaceutical Research</i> , <b>2021</b> , 38, 795-801	4.5	2
26	Recent developments in and models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. <i>Drug Metabolism Reviews</i> , <b>2021</b> , 53, 207-233	7	3
25	Recent advances in computational metabolite structure predictions and altered metabolic pathways assessment to inform drug development processes. <i>Drug Metabolism Reviews</i> , <b>2021</b> , 53, 173-187	7	0
24	Recent developments in predicting CYP-independent metabolism. <i>Drug Metabolism Reviews</i> , <b>2021</b> , 53, 188-206	7	1
23	There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. <i>AAPS Journal</i> , <b>2021</b> , 23, 67	3.7	4
22	Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 480-485	6.1	0
21	Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 205-222	6.2	6
20	Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). <i>Methods in Molecular Biology</i> , <b>2021</b> , 2342, 765-779	1.4	
19	Advances in the study of drug metabolism - symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX). <i>Drug Metabolism Reviews</i> , <b>2020</b> , 52, 395-407	7	8
18	A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 306-315	6.1	5
17	Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kp) on Prediction of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , <b>2020</b> , 37, 73	4.5	4
16	Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?. <i>Drug Metabolism and Disposition</i> , <b>2020</b> , 48, 537-543	4	10
15	Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. <i>Pharmaceutical Research</i> , <b>2020</b> , 37, 208	4.5	7

14	Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. <i>AAPS Journal</i> , <b>2020</b> , 22, 120	3.7	8
13	The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. <i>AAPS Journal</i> , <b>2020</b> , 22, 111	3.7	6
12	How Transporters Have Changed Basic Pharmacokinetic Understanding. <i>AAPS Journal</i> , <b>2019</b> , 21, 103	3.7	16
11	Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2019</b> , 46, 155-163	2.7	15
10	The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. <i>Pharmaceutical Research</i> , <b>2018</b> , 35, 242	4.5	14
9	Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	5
8	The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters. <i>Drug Metabolism Letters</i> , <b>2017</b> , 11, 111-118	2.1	6
7	Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 8345-68	8.3	13
6	A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 908-15	4	48
5	Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. <i>Drug Metabolism Reviews</i> , <b>2015</b> , 47, 291-319	7	10
4	1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 813-7	4	12
3	For a series of methylindole analogs, reactive metabolite formation is a poor predictor of intrinsic cytotoxicity in human hepatocytes. <i>Toxicology Research</i> , <b>2014</b> , 3, 184	2.6	4
2	Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2013</b> , 23, 3531-8	2.9	24
1	Association of CYP2C9*2 with bosentan-induced liver injury. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 678-86	6.1	43